Filipino Filipino
en Englishaf Afrikaanssq Albanianar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbg Bulgarianca Catalanzh-CN Chinese (Simplified)zh-TW Chinese (Traditional)hr Croatiancs Czechda Danishnl Dutchet Estoniantl Filipinofi Finnishfr Frenchgl Galicianka Georgiande Germanel Greekht Haitian Creoleiw Hebrewhi Hindihu Hungarianis Icelandicid Indonesianga Irishit Italianja Japaneseko Koreanlv Latvianlt Lithuanianmk Macedonianms Malaymt Malteseno Norwegianfa Persianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesecy Welshyi Yiddish

Pinakabagong Balita

Enhanced Factor IX Aktibidad kasunod ng Pamamahala ng AAV5-R338L "Padua" Factor IX kumpara sa AAV5 WT Human Factor IX sa NHPs

Enhanced Factor IX Aktibidad kasunod ng Pamamahala ng AAV5-R338L "Padua" Factor IX kumpara sa AAV5 WT Human Factor IX sa NHPs

Spronck EA, et al. Enhanced Factor IX Aktibidad kasunod ng Pamamahala ng AAV5-R338L "Padua" Factor IX kumpara sa AAV5 WT Human Factor IX sa NHPs. Mga Pamamaraan ng Mol Ther Clin Dev. 2019; 15: 221 231-.

Back To Top
Imahen

Please enable the javascript to submit this form

tungkol sa

Sinusuportahan ng mga grant na pang-edukasyon mula sa Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, at uniQure, Inc.

Mahalagang SSL